Watch hVIVO’s July 2024 Capital Markets Day here
We are a full-service Contract Research Organisation (CRO) and the global leader in human challenge trials. The Company delivers end-to-end clinical development services to a diverse and expanding client base, including seven of the world’s ten largest biopharma companies.
Yamin 'Mo' Khan
CEO at hVIVO
"The utility of our services remains strong, as demonstrated by the recent success of our client's Phase II candidate. Our diversification strategy is already delivering results, and we expect continued momentum across all revenue streams. While macroeconomic and sector-specific headwinds are still affecting contract conversions, we remain confident in the long-term growth trajectory of our services and the overall prospects for hVIVO. I'm encouraged by the strength of our sales pipeline, with several major opportunities that could enhance the growth of our services. We believe that we are well positioned to deliver growth in FY26, and we look forward to keeping shareholders updated on our progress."
H1 25 Revenue
H1 25 EBITDA Margin
Cash 30 June 2025
FY24 Guidance
Sign up to our emails and follow us on social media to keep up to date with hVIVO.
